A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma

Ankyra Therapeutics

Status and phase

Not yet enrolling

Phase 1

Conditions

Solid Tumor Cancer

Solid Tumor

Cutaneous Squamous Cell Carcinoma (CSCC)

Renal Transplant

Treatments

Drug: tolododekin alfa

Study type

Interventional

Funder types

Industry

Identifiers

NCT07100925

ANK-101-003

Details and patient eligibility

About

A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).

Enrollment

20 estimated patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have histologically or cytologically confirmed high-risk and/or locoregionally metastatic CSCC
Have measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Are renal allograft recipients on a stable immunosuppressive regimen.
Have adequate renal function defined as creatinine clearance ≥ 30 mL/min as determined by the Cockcroft-Gault equation.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Have a life expectancy > 12 months.
Have baseline electrocardiogram (EKG) without evidence of acute ischemia or prolonged QT interval
Heterosexually active women of childbearing potential (WOCBP) must agree to use at least 2 forms of highly effective methods of contraception
All male participants who are not sterile must commit to the use of a reliable method of birth control or abstinence.
Last dose of previous anticancer therapy (including investigational agents) ≥ 28 days or surgical intervention ≥ 21 days prior to the first dose of study drug.
Resolution of all prior anticancer therapy toxicities (except for alopecia or vitiligo) to ≤ Grade 1
Willingness to provide fresh tumor biopsy specimens
Capable of understanding and complying with protocol requirements.
Provides written informed consent for the study.

Exclusion criteria

Have AJCC Stage IV disease, known distant metastasis, or findings on imaging that are considered to be highly suspicious for distant metastasis.
Have injectable tumors impinging upon major airways or blood vessels.
Have had prior treatment with recombinant interleukin-12 (IL-12).
Have had prior radiation therapy within 28 days for CSCC at the site of injection.
Have received live vaccines within 28 days prior to the start of study drug (C1D1).
Have any history of transplant-related deoxyribonucleic acid (DNA) viral infections, such as human polyomavirus 1 (BKV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) within 3 months of C1D1.
Have primary or acquired immunodeficient states (e.g., leukemia, lymphoma) requiring active therapy.
A WOCBP who has a positive serum pregnancy test prior to C1D1 or female participant who is breastfeeding
Have known active uncontrolled hepatitis B, hepatitis C (HCV), or human immunodeficiency virus (HIV) infection.
Have active autoimmune disease or medical conditions requiring chronic steroid (i.e., ≥ 20 mg/day prednisone or equivalent) or other immunosuppressive therapy beyond that required for maintenance allograft rejection prevention.
Have congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or clinically significant cardiac arrhythmias.
Have uncontrolled bleeding disorders.
Have a history of allergic reactions attributed to compounds of similar biological composition to IL-12, aluminum hydroxide, or drugs formulated with polysorbate-20.
Have other systemic conditions or organ abnormalities that may interfere with the conduct the current study.
Have any acute or chronic psychiatric problems or substance abuse disorder that make the participant unsuitable for participation.